Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Stage I Mixed Cell Type Kidney Wilms Tumor 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Intraductal Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Carcinosarcoma 1Burkitt Lymphoma 1Anus Neoplasms 1Anal Canal Carcinoma 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 2X-Rays 2Taxes 2Specimen Handling 2Paclitaxel 2Carboplatin 2Radiation 1Phantoms, Imaging 1Minimally Invasive Surgical Procedures 1Magnetic Resonance Spectroscopy 1Indocyanine Green 1Ifosfamide 1Congresses as Topic 1Brachytherapy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinosarcoma × Phantoms, Imaging × Clear all
NCT04214067 2026-05-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
164 enrolled
Sarcoma

Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡